AI-driven Breast Cancer Diagnostics in Mobile Devices: Pioneering Efforts by Polish Firms
Breaking ground in health innovation, two trailblazing Polish firms, AILIS and Sobiesław Zasada Automotive, are gearing up to disrupt breast cancer diagnostics with the introduction of cutting-edge mobile diagnostic centers, fueled by artificial intelligence (AI). The partnership was officially cemented at the Economic Forum in Karpacz. Their mission is simple: bring high-quality breast cancer screening services to underserved regions, giving women in Poland and beyond equitable access to early detection.
Moving Diagnostics to the People
The unstoppable alliance between AILIS and Sobiesław Zasada Automotive will birth self-sustaining, eco-friendly mobile diagnostic laboratories. Equipped with AI technology, these mobile units will provide premium breast cancer screening services, rivaling the best stationary medical facilities. Their primary objective is to dismantle geographical barriers, making it possible for high-quality diagnostics to infiltrate smaller towns and remote areas where specialized medical services are scarce.
Michał Matuszewski, CEO of AILIS, expressed their intentions in a statement: "Our mobile diagnostic centers will seek out women, erasing geographical obstacles and ensuring top-tier care. This project embodies the global trend towards equality in healthcare access."
AI-Empowered Breast Cancer Detection
AILIS boasts a proprietary diagnostic system that harnesses Parametric Dynamic Imaging and AI algorithms to detect breast cancer at its early stages. What sets this new diagnostic method apart is its non-invasive approach, avoiding radiation, eliminating compression, and enabling frequent, painless testing. Shockingly, results will be available in just 10 minutes.
Maciej Rżysko, Vice President of Sobiesław Zasada Automotive, echoed his pride: "We are honored to take part in this groundbreaking project, impacting women's health directly. With AILIS, we're seeing Poland emerge as a leader in mobile, advanced diagnostic units."
Driven by Sustainable Technology
These mobile centers will be stationed on the Mercedes-Benz eActros 600, an advanced electric vehicle celebrated for its long range and reliability. This eco-friendly platform aligns perfectly with the project's sustainability goals, ensuring that high-quality diagnostics are delivered without harming the environment.
The AI-driven diagnostic system developed by AILIS aligns with the United Nations' objectives regarding health improvement and reduction of healthcare disparities. By partnering with Sobiesław Zasada Automotive, AILIS aims to drive sustainable development while significantly improving women's health outcomes.
Taking on the Breast Cancer Pandemic
Breast cancer poses a grave threat to the health of women in Poland. Every day, 58 Polish women are diagnosed with the disease, and 17 die from it. The early detection rate of breast cancer in Poland stands at only 41%, one of the lowest rates in Europe. Additionally, the country experiences the highest mortality rate for breast cancer within the European Union, compounded by a shortage of healthcare professionals.
To combat these challenges, AILIS has designed its AI-powered diagnostic system to offer rapid, reliable, and frequent screenings, potentially increasing early detection rates. By making diagnostics accessible, AILIS seeks to turn the tide against breast cancer in Poland and other countries.
A Glimmer of Hope for the Future
Currently under clinical evaluation, the AILIS system is set to debut in Poland initially, followed by international markets. Future ambitions involve expanding the system to integrate a digital assistant capable of monitoring breast health, suggesting regular check-ups, and assessing individual cancer risk based on patient data.
This innovative project signifies a promising stride toward tackling the global breast cancer crisis, especially in regions where access to early detection is limited. As Poland establishes itself as a pioneer in AI-driven mobile healthcare, the impact of this collaboration between AILIS and Sobiesław Zasada Automotive could revolutionize breast cancer care for women worldwide.
Oh hi there, It's great to meet you!
Join our mailing list to receive our weekly update on News from Poland.
Every Saturday.
No spam*!
Check your inbox or spam folder to confirm your subscription.
We don't spam!
- AILIS and Sobiesław Zasada Automotive are partnering to launch mobile diagnostic centers equipped with AI technology, aiming to bring high-quality breast cancer screening services to underserved regions.
- The partnership's self-sustaining, eco-friendly mobile diagnostic laboratories will offer premium breast cancer screening services, rivaling the best stationary medical facilities.
- The mission is to dismantle geographical barriers, making it possible for high-quality diagnostics to infiltrate smaller towns and remote areas where specialized medical services are scarce.
- The proprietary diagnostic system developed by AILIS uses Parametric Dynamic Imaging and AI algorithms to detect breast cancer at its early stages, employing a non-invasive approach.
- Results will be available in just 10 minutes, and the method eliminates radiation, compression, and allows for frequent, painless testing.
- The mobile centers will be stationed on the Mercedes-Benz eActros 600, an advanced electric vehicle with long range and reliability, aligning with the project's sustainability goals.
- The AI-driven diagnostic system developed by AILIS aims to reduce healthcare disparities and drive sustainable development while significantly improving women's health outcomes.
- Breast cancer poses a severe threat to women's health in Poland, with every day 58 Polish women diagnosed, and 17 dying from the disease.
- The early detection rate of breast cancer in Poland stands at only 41%, one of the lowest rates in Europe, while the country experiences the highest mortality rate for breast cancer within the European Union.
- To combat these challenges, AILIS has designed its AI-powered diagnostic system to offer rapid, reliable, and frequent screenings, potentially increasing early detection rates.
- Currently under clinical evaluation, the AILIS system is set to debut in Poland initially, followed by international markets.
- Future ambitions involve expanding the system to integrate a digital assistant capable of monitoring breast health and assessing individual cancer risk based on patient data, further revolutionizing breast cancer care.
